The overall prevalence of HBV/HDV co-infection was determined to be 8%, with cirrhosis present in 73% of the co-infected, 80% of the tri-infected (HDV/HBV along with hepatitis C infection), but only 22% of HBV mono-infection.
Comprehensive insight on patient segmentation based on Age group, Sex, Isolates (Genotype – I, II & III), co-infection with HDV and HBV of a susceptible, anti-HBs-negative individual, and HDV superinfection of a chronic HBV carrier, Type of settings (Acute & Chronic) has been provided into the epidemiology (Incidence and Prevalence) section of the HDV and its treatment in the 8 MM coun-tries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
Despite interferon-a (IFNa) & Peg-iFn-? usage, the primary concern is the prevention of the progression of the disease and its lateral damages such as cirrhosis, liver failure, and carcinoma. Currently companies like Roche; Pegasys, Replicor Inc.; REP 2139-Ca + Pegasys, MYR Pharma; Myrcludex B, Eiger BioPharmaceuti-cals; Lonafarnib, Eiger BioPharmaceuticals; Pegylated interferon lambda 1a. The market is expected to witness rapid growth with the launch of designated emerging therapies, such as Myrcludex B; MYR Pharma (Orphan designation), Lonafarnib; Eiger BioPharmaceuti-cals (Fast Track & Orphan designation). Myrcludex B showed a strong effect on HDV RNA serum levels and induced ALT normalization under monotherapy. Among the key assets, some of the companies like Merck Sharp & Dohme Corp., Gilead Sciences, Arrowhead Pharmaceuticals, and Boehringer Ingelheim are in the race to build their assets within the market space
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,